Home » Covid is no longer scary: the accounts of Pfizer, BioNTech and Moderna are deflating

Covid is no longer scary: the accounts of Pfizer, BioNTech and Moderna are deflating

by admin
Covid is no longer scary: the accounts of Pfizer, BioNTech and Moderna are deflating

Covid is no longer scary, an alarm for the business of Pfizer, BioNTech and Moderna

From health emergency to “peaceful” coexistence: the “new” Coronavirusat least in the West, where a vaccination campaign ad hoc, it’s no longer scary. THE severe cases by now, the doctors explain, they are rareThe hospitals not I am more clogged. The virus now appears to be domesticated: he is more contagious but he has weakened. In terms of symptoms, such as loss of taste and smell, they have almost disappeared, while more or less serious affections of the respiratory system remain. However, the impact on hospitals is minimal, and overall, the pandemic, what was terrifying up to a year ago, is no longer “scary”.

And if on the one hand, on the health front, the situation seems to have improved, on the other hand, the consequences are now “paying” for the accounts of big del pharma. According to what he writes breaking latest news in fact “the three owners of the most widespread and expensive anti-Covid vaccines: Pfizer, BioNTech and Moderna in 2021 they grossed about 90 billion dollars, with profits hovering around 41 billion”. But now the free ride is over, the vein of gold has dried up and companies are running for cover. Just look at some numbers.

READ ALSO: Big Pharma finances 70% of US parliamentarians. In Italy still ombre

Pfizer, the American pharmaceutical giant, in the latest quarterly forecasts a sharp decline in annual sales in 2023 due to the easing of the pandemic emergency and the reduced contributions of its Covid-19 vaccine and antiviral medicine. From the record level of $100.3 billion in 2022 revenues Pfizer will drop a lot this year and doesn’t estimate it will go beyond $67-73 billion.

See also  RMB Strengthening Against USD as Profits Surge: U.S. Treasury Secretary Yellen's Visit to China and Caixin Manufacturing PMI in Focus

The company also cut a lot on earnings and from the record level of $6.58 per share in 2022, it will drop to $3.25-3.45, well below analysts’ expectations, which are $4.42 to action. Same fate also for Moderna. According to the estimates of Airfinitya scientific information and analytics company that works with pharmaceutical companies, governments, investors and the media, the revenue of Modern they have risen to around 18 billion dollars in 2022, precisely due to the fact that the company has supplied governments with bivalent vaccines. There are no reliable estimates for this year, but it should record a drop in sales of around 62-63%, similar to that of Pfizer/BioNTech.

READ ALSO: Vaccines, drop in demand but Big Pharma bills the same. Prices doubled

Subscribe to the newsletter

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy